You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Article metrics

Article menu

Download PDFPDF

XML
Clinical trials and drug discovery
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

 

Online download statistics by month:

Online download statistics by month: April 2018 to December 2022

AbstractFullPdf
Apr 2018513521107
May 2018402418111
Jun 201827828583
Jul 201824424470
Aug 201838938880
Sep 2018371371101
Oct 201833633688
Nov 201829529591
Dec 201818418340
Jan 201919418596
Feb 201920820589
Mar 2019227224302
Apr 2019252238285
May 2019132127199
Jun 2019126120247
Jul 2019135136243
Aug 2019210198318
Sep 2019164159280
Oct 2019140134248
Nov 2019203196362
Dec 2019190184169
Jan 2020417408347
Feb 2020173161210
Mar 202014113889
Apr 2020969396
May 202011511076
Jun 2020888276
Jul 2020948691
Aug 202011010476
Sep 202014511898
Oct 202014412881
Nov 202013012887
Dec 202011711568
Jan 202112111164
Feb 202115814872
Mar 202112912087
Apr 202111710885
May 202115014566
Jun 202113212168
Jul 202112611454
Aug 2021190167114
Sep 202115114289
Oct 202116015094
Nov 2021228202109
Dec 202112011460
Jan 202215814669
Feb 2022180169103
Mar 2022187179109
Apr 202218717984
May 202226326585
Jun 202219117375
Jul 202216115170
Aug 202217215847
Sep 202215714579
Oct 202215814985
Nov 202214914389
Dec 202212816463
Total10836104816924